News & Announcements
PharmaJet Secures Series C
December 16, 2011
PharmaJet, Inc., a developer of needle-free injection technology, has closed a Series C round of financing.
PharmaJet’s needle-free injection technology delivers liquid drugs and vaccines to intramuscular, subcutaneous and intradermal tissue depths. PharmaJet injectors use pressure to create a fine stream of liquid that penetrates the skin, delivering doses to the desired depth, while eliminating needle-stick risk and the burden of sharps waste management.
PharmaJet’s investors include Hearthstone Investments, Kulik Investments, Baring Communications Equity (Emerging Europe) Limited, and private investors.
A Denver-based company, PharmaJet opened an office in Baltimore at the University of Maryland BioPark in April 2010.